Skip to main content

Cost-effective reimbursement analysis for medical technologies in Europe

Procedure coding, payment mechanism, reimbursement tariffs, policy, and HTA considerations in 20 EU countries

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Publication Digest: Integration of real-world evidence from different data sources in health technology assessment

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Graili et al. reviewed the comprehensive integration of real-world evidence (RWE) drawn from diverse sources of real-world data (RWD) within the health technology assessment (HTA) process. The authors examined the potential challenges and barriers that impede the widespread incorporation of RWE in routine HTA practices. The study sheds light on the effective utilization of RWE, offering insights into the strategic application of RWD at different stages of the HTA process, thus advocating for a more robust and inclusive approach to evidence-based decision-making in healthcare.

Access the full-text article here.